FDA Requires Visual Warning on All GLP-1 Drugs After 6.4 NAION Cases per 100,000 Person-Years
Key Facts
The U.S. Food and Drug Administration said on November 9, 2026, that it will require the holders of licenses for all GLP-1 receptor agonist drugs to add information about a possible increased risk of non-arteritic anterior ischemic optic neuropathy, known as NAION, to the warnings and precautions section of their labeling. The decision extends the labeling update requirement across the entire drug class, which is widely used to treat type 2 diabetes, reduce weight and maintain long-term weight loss. The announcement followed a review of clinical trial, animal, post-marketing and observational study data. The agency said its findings point to a "potential increased risk" associated with use of these drugs. The warning responds to a vision-related safety signal, while the size of the risk remains subject to cautious interpretation given differences in the analyses.
In a meta-analysis of 126 clinical trials, the incidence rate of NAION among users of GLP-1 drugs was about 6.4 cases per 100,000 person-years, compared with 3.8 cases among patients who received comparator drugs. The analysis included 134,253 patients, of whom 78,217 used GLP-1 drugs and 56,036 received a comparator treatment, with total exposure of 288,879 person-years. The analysis translated these rates into 15 potential cases in the trials: 10 among GLP-1 users and five among placebo recipients. No cases were observed among patients who received other blood-sugar-lowering drugs outside the GLP-1 class. The figures show that the number of recorded cases was limited within a large participant base and exposure period, while the observed rate remained higher among users of the class than in the comparator group.
The agency also drew on observational studies of people with type 2 diabetes who started treatment with GLP-1 drugs, comparing them with patients who started DPP-4 or SGLT-2 inhibitors. It said studies it described as methodologically rigorous consistently showed a higher risk of NAION among those who started GLP-1 drugs, and that their findings were generally consistent with the agency's analyses. But one real-world comparison found no statistically significant increase in risk versus SGLT-2 inhibitors. That finding limits what can be inferred from the signal: the statistical significance of results varied by analysis and comparator group. The agency therefore framed its conclusion as a potential increase in risk, not proof of a settled causal relationship.
A study of NAION risk among patients prescribed semaglutide was published in July 2024. The agency said it identified several limitations in that study, but considered the findings sufficient to warrant further evaluation of a possible increased risk. The agency subsequently reviewed evidence across multiple sources, including clinical trials, animal data, post-marketing reports and observational studies. This sequence places the study within a broader assessment that preceded the labeling update requirement. To provide context on the rarity of the condition, published literature cited by the agency indicates an incidence rate ranging from 2.3 to 10.2 cases per 100,000 people annually among adults over age 50.
The agency described NAION as a rare condition that can cause a sudden, painless loss of vision in one eye and may lead to permanent vision loss, while its underlying cause is not fully understood. Symptoms warranting attention include sudden, painless vision loss, blind spots, tunnel vision or distorted color vision. The agency recommends that anyone experiencing these symptoms contact a health professional immediately. Anyone who has experienced NAION should discuss whether to continue taking or stop a GLP-1 drug with their health care provider. The guidance provides a practical course of action for symptoms, while any decision to change treatment remains an individual discussion with a specialist.